Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry

Fig. 2

IRRs of SIEs, malignancies, and CVEs between the CZP and other TNFi groups. a Before PS matching (all initiators). b After PS matching. IRRs were calculated with the CZP group in the numerator and the other TNFi in the denominator. IRR Incidence rate ratio, SIE Serious infectious event, CVE Cardiovascular event, CZP Certolizumab pegol, TNFi Tumor necrosis factor inhibitor, PS Propensity score

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us